{"preliminary_commentary":{"by_channel":{"youtube":4,"x_thread":3,"podcast":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02426086\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"IMbark","nct_id":"NCT02426086","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imbark-nct02426086. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Imetelstat 4.7 mg/kg","type":"EXPERIMENTAL"},{"description":null,"label":"Imetelstat 9.4 mg/kg","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2020-02-07","type":"ACTUAL"},"conditions":["Myelofibrosis"],"enrollment":{"count":107,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Imetelstat 4.7 mg/kg","otherNames":[],"type":"DRUG"},{"name":"Imetelstat 9.4 mg/kg","otherNames":[],"type":"DRUG"}],"last_update":"2021-09-14","lead_sponsor":"Geron Corporation","official_title":"A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2018-04-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Spleen Response","timeFrame":"Week 24"},{"measure":"Percentage of Participants With Symptom Response","timeFrame":"Week 24"}],"references":[{"citation":"Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 Sep 10;39(26):2881-2892. doi: 10.1200/JCO.20.02864. Epub 2021 Jun 17.","pmid":"34138638","type":"DERIVED"}],"start_date":{"date":"2015-08-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor","url":"https://clinicaltrials.gov/study/NCT02426086"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imbark-nct02426086"}